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Background: Cyclophellitol-derived activity-based probes label the nucleophile of retaining -glucosidases by exploiting
their catalytic mechanism.
Results: Combining two distinct cyclophellitol-derived probes with azide-mediated activity-rescue of mutated retaining -glu-
cosidases enables acid/base residue identification.
Conclusion: A sensitive, new gel-based method for catalytic residue identification is developed.
Significance: Cyclophellitol-based probes are proposed as useful tools for the identification of catalytic residues in retaining
glycosidases.
Retaining -exoglucosidases operate by a mechanism in
which the key amino acids driving the glycosidic bond hydroly-
sis act as catalytic acid/base and nucleophile. Recently we
designed two distinct classes of fluorescent cyclophellitol-type
activity-based probes (ABPs) that exploit this mechanism to
covalently modify the nucleophile of retaining -glucosidases.
Whereas -epoxide ABPs require a protonated acid/base for
irreversible inhibition of retaining -glucosidases, -aziridine
ABPs do not. Here we describe a novel sensitive method to iden-
tify both catalytic residues of retaining -glucosidases by the
combined use of cyclophellitol -epoxide- and -aziridine
ABPs. In this approach putative catalytic residues are first sub-
stituted to noncarboxylic amino acids such as glycine or gluta-
mine through site-directed mutagenesis. Next, the acid/base
and nucleophile can be identified via classical sodium azide-
mediated rescue of mutants thereof. Selective labeling with fluo-
rescent -aziridine but not -epoxide ABPs identifies the acid/
base residue in mutagenized enzyme, as only the -aziridine
ABP can bind in its absence. The Absence of the nucleophile
abolishes any ABP labeling. We validated the method by using
the retaining -glucosidase GBA (CAZy glycosylhydrolase fam-
ily GH30) and then applied it to non-homologous (putative)
retaining -glucosidases categorized in GH1 and GH116:
GBA2, GBA3, and LPH. The described method is highly sensi-
tive, requiring only femtomoles (nanograms) of ABP-labeled
enzymes.
Retaining -glucosidases hydrolyze glycosidic bonds in var-
ious endogenous and natural exogenous substrates. In man the
documented retaining -glucosidases fulfill important physio-
logical functions. They belong to different CAZy glycosylhy-
drolase families (GH1,5 GH30 and GH116; see Fig. 1a), a clas-
sification system based on their amino acid sequence, catalytic
mechanism, structure, and active site residues (1). Human lys-
osomal glucocerebrosidase (GBA; categorized in CAZy family
GH30) degrades glucosylceramide, and its deficiency causes
Gaucher disease, a relatively common lysosomal storage disor-
der (2– 4). Carriers of GBA mutations are at increased risk for
developing Parkinsonism (5, 6). Non-lysosomal -glucosidase
(GBA2; GH116) converts glucosylceramide to ceramide at the
cytosolic leaflet of membranes (7–9) and has been implicated in
ceramide-driven apoptosis (10). GBA2 deficiency was recently
also linked to a neurological disorder (11, 12). Cytosolic -glu-
cosidase GBA3 (GH1) hydrolyzes xenobiotic -glucosides in
the cytosol (13, 14), and GBA3 deficiency is not associated with
a health risk (15). Deficiency of lactase-phlorizin hydrolase
(LPH; GH1), an intestinal enzyme containing a functional
-glucosidase pocket next to a -galactosidase pocket, causes
lactose intolerance (16 –19). Finally, klotho, klotho, and
KLPH (klotho) share homology with the amino acid sequence
of LPH and GBA3 and are also categorized in GH1, but all lack
functional -glucosidase activity (20 –25). Klotho has been
reported to have -glucuronidase activity toward artificial sub-
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strates when fused with an extracellular domain (24, 25),
whereas sialidase activity has also been reported (26). The
klotho proteins interact with FGF and FGF receptors, modulat-
ing endocrine axes that regulate various metabolic processes
(27). Klotho is involved in aging processes (20), whereas
klotho is essential in bile acid homeostasis and the activity of
brown adipose tissue (21).
Retaining -glucosidases hydrolyze glucosidic substrates
through a two-step double-displacement mechanism driven by
a discriminate nucleophile and acid/base residue (Fig. 1, a and
b) (18). In the first step the nucleophile attacks the anomeric
carbon of the glucose moiety, whereas the acid/base residue
protonates the interglucosidic oxygen, resulting in aglycone
release and concomitant nucleophile glucosylation (28). In the
second step enzyme deglucosylation is promoted by activation
of an incoming water nucleophile by the deprotonated acid/
base, completing the hydrolysis event with overall retention of
configuration at the anomeric carbon of the released glucose
molecule.
Recently we reported the development of two different activ-
ity-based probe (ABP) classes for retaining -glucosidases (29,
30). The first class concerns cyclophellitol (-epoxide) deriva-
tives functionalized with a fluorescent BODIPY moiety grafted
to the C8 position (MDW933, hereafter named ABP 1; see Fig.
1c) (29). They bind irreversibly to the nucleophile Glu-340 of
GBA in an acid/base-dependent manner; the acid/base residue
protonates the -epoxide, which is concomitantly attacked by
the nucleophile; thereby the oxirane opens and forms a stable
ester bond with the nucleophile residue (Fig. 1d) (29, 30). Aziri-
dine analogs of cyclophellitol functionalized with a BODIPY
group grafted to the -aziridine nitrogen comprise the other
ABP class (MDW1044, hereafter named ABP 2; see Fig. 1c) (30).
These bind nucleophiles of various -glucosidases through a
similar mechanism but that can occur independently of the
acid/base status (Fig. 1e) (30).
An elegant method has been developed in the past to identify
the nucleophile and acid/base residues of retaining glycosi-
dases, namely by using (sodium) azide as an exogenous anion
FIGURE 1. Background. a, protein sequence homology of all retaining -glucosidases expressed in man, categorized in glycosylhydrolase families GH1, -30,
and -116. b, double displacement mechanism of retaining -glucosidases, with distinct acid/base (A/B, top) and nucleophile (N, bottom). c, structure formulas
of cyclophellitol-based ABP 1 (MDW933 (29)) and aziridine containing ABP 2 (MDW1044 (30)) and their nucleophile binding mechanisms (d and e, respectively).
Azide-mediated rescue of hydrolysis in case of absent acid/base (f) or nucleophile (g).
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that can function as a substitute for the acid/base or nucleophile
residue, allowing the rescue of substrate hydrolysis by enzyme
molecules with a mutated catalytic residue (Fig. 1, f and g) (31–
33). In this approach, definite identification of the acid/base
and nucleophile can be achieved by determining the azido-
product stereochemistry via NMR. In retaining -glucosidases,
sodium azide-mediated rescue results in retention of stereo-
chemistry in the case of acid/base absence (-azidoglucoside;
Fig. 1f) and inversion of stereochemistry when the nucleophile
is lacking (-azidoglucoside; Fig. 1g) (31–33). Success of this
method hinges on the ability to isolate and identify the nature of
the glucosazide adduct formed, which essentially means that
the approach works best when executed on isolated, soluble
mutant glycosidases.
In a series of related studies, Withers et al. (28, 34 –37) have
employed various 2-deoxy-2-fluoroglycosides to identify the
nucleophile of retaining -glycosidases by trapping the nucleo-
phile. Covalent and (semi)permanent modification of the
nucleophilic residues in retaining -glucosidases occurs due to
the substitution of the C2-hydroxyl by a fluorine, which mark-
edly destabilizes the positive charge developed during the oxo-
carbenium ion-like transition states flanking the covalent gly-
cosyl-enzyme intermediate, thereby effectively reducing the
catalytic rates involved in the double-displacement mechanism
by up to 107-fold. Identification of the thus covalently and irre-
versibly modified nucleophile in this setting is achieved by mass
spectrometry analysis of trypsin-digested protein, and the
method thus relies on labeling of pure, recombinant enzyme
with 2-deoxy-2-fluoroglycosides.
We here report a new and complementary method for the
identification of the acid/base and nucleophile residues in the
known human retaining -glucosidases. Our approach entails a
combination of site-directed mutagenesis, subsequent identifi-
cation of putative catalytic residues by sodium azide-mediated
rescue of enzymatic activity, and finally discrimination between
the acid/base and nucleophile by detection of ABP 2-labeled
-glucosidases on slab-gels. The ABP labeling of retaining
-glucosidases is characterized by high sensitivity and selectiv-
ity, allowing visualization of femtomoles, i.e. nanograms, of
enzymes within complex mixtures such as cell extracts.
As model we first used GBA (CAZy family GH30) with
known nucleophile residue Glu-340 and acid/base residue Glu-
235 to validate our method (39). Next, we studied GBA3 (CAZy
GH1) for which crystal data predicted Glu-165 and Glu-373 as
acid/base and nucleophile, respectively (40). In addition, LPH
(GH1), with known catalytic residues in its two pockets (41),
was investigated. Finally we studied the enzyme GBA2.
Recently, the acid/base and nucleophile of a distant GBA2
homologue in Sulfolobus solfataricus (GH116) have been iden-
tified via azide rescue and covalent labeling of the nucleophile
with 2-deoxy-2-fluoroglucoside (42). Based on homology align-
ment, the acid/base and nucleophile in human GBA2 were ten-
tatively appointed previously (42) and by our own work, and
these are in line with the residues predicted from the GBA2-
homologue in S. solfataricus. We also demonstrate through
application of our ABP methodology that none of the proteins
klotho, klotho, and KLPH (GH1) possesses -glucosidase
activity.
EXPERIMENTAL PROCEDURES
General Methods—ABP 1 and ABP 2 were synthesized as
described earlier (29, 30). Chemicals were obtained from Sigma
if not otherwise indicated. Recombinant GBA (imiglucerase)
was purchased from Genzyme. COS-7 cells were cultured in
Ham’s F-12-DMEM (Invitrogen) supplied with 10% (v/v) FCS.
Amino acid sequence alignments were performed in Clustal-
Omega 1.2.0, and (putative) catalytic residues were identified
through entries in UniProt P04062 (GBA), Q9HCG7 (GBA2),
Q9H227 (GBA3), P09848 (LPH), Q9UEF7 (klotho), Q86Z14
(klotho), and Q6UWM7 (KLPH).
Molecular Cloning and Site-directed Mutagenesis—The
design of cloning primers for mutation introduction was
based on NCBI reference sequences NM_000157.3 (GBA),
NM_020944.2 (GBA2), NM_020973.3 (GBA3), NG_008104.2
(LPH), NM_004795.3 (klotho), NM_175737.3 (klotho), and
NM_207338.2 (KLPH). All full-length cDNA sequences were
cloned into pcDNA3.1 in-frame with the myc/His vector (Invit-
rogen). Site-directed mutagenesis was performed using the
QuikChange II XL site-directed mutagenesis kit (Agilent Tech-
nologies) with primers shown in Table 1.
Protein Expression and Isolation—Confluent COS-7 cells
were transfected with empty pcDNA3.1 vector (Mock) or the
vector with the described insert, in conjunction with FuGENE
(Roche Applied Science) and harvested after 72 h by scraping in
25 mM potassium phosphate buffer (pH 6.5, supplemented with
0.1% (v/v) Triton X-100 and protease inhibitor mixture (Roche
Applied Science)). After determination of the protein concen-
tration (BCA kit, Pierce), lysates were aliquoted and frozen at
80 °C.
Enzyme Activity Assays—All assays were performed at 37 °C.
Cellular extracts were preincubated for 30 min with inhibitors
of GBA (1 mM conduritol -epoxide; IC50 9.49 mM) (29, 30)
and/or GBA2 (20 nM N-(5-adamantane-1-yl-methoxy)pentyl)-
deoxy-nojirimycin (AMP-DNM), IC50 2 nM) (43, 44) to distin-
guish the activity of the enzyme of interest. GBA activity was
measured in 150 mM McIlvaine buffer (pH 5.2) supplemented
with 0.2% (w/v) sodium taurocholate, 0.1% (v/v) Triton X-100,
protease inhibitor mixture (Roche Applied Science), and 0.1%
(w/v) BSA. -Glucosidase activities of GBA2, GBA3, and LPH
were measured in McIlvaine buffer without detergents at pH
5.8, 6.5, and 6.0, respectively. Where specified, enzyme assays
were performed with 3.75 mM fluorescent 4-methylumbel-
liferyl--D-glucopyranoside (4MU--D-Glc), chromogenic 20
mM 4-nitrophenyl -D-glucopyranoside (4NP--D-Glc), or 20
mM 2,4-dinitrophenyl -D-glucopyranoside (2,4DNP--D-Glc).
Lactase -galactosidase activity was quantified by measuring
liberated D-glucose from 100 mM lactose (38). Measurements of
ABP 1 and 2 IC50 for overexpressed LPH were performed by
preincubating cell lysates with an appropriate range of inhibitor
dilutions for 30 min at 37 °C, after which residual -galactosid-
ase and -glucosidase activities were measured with 100 mM
lactose (38) and 3.75 mM 4MU--D-Glc (29, 30), respectively.
After 90 min, all enzymatic reactions were stopped with 3 M
NaOH-glycine (pH 10.8), and liberated 4MU was fluorimetri-
cally determined at EX 365 nm, EM 425 nm (29, 30). Reactions
with 4NP--D-Glc and 2,4DNP--D-Glc were quenched
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through the addition of excess 1 M ice-cold Na2CO3 (pH 10.2),
and absorption of 4NP and 2,4DNP was determined at ABS 405
nm (molar extinction coefficients 4NP 8.94 M1 cm1 and
2,4DNP 9.27 M1 cm1, respectively).
In Vitro ABP Labeling—Cell extracts (10 g of total protein)
were labeled with ABP 1 or 2 in appropriate McIlvaine buffer
without BSA at 37 °C in 40-l total volume: GBA, GBA2 were
labeled with 1 M ABP for 1 h; GBA3, LPH with 10 M ABP for
1 h; klotho, klotho and KLPH with 1 mM for 18 h. After label-
ing and when applicable, His-tagged proteins were purified
with TALON beads following manufacturer’s instructions
(Clontech). Samples were then denatured with 5 Laemmli
buffer (50% (v/v), 1 M Tris-HCl (pH 6.8), 50% (v/v) 100% glyc-
erol, 10% (w/v) DTT, 10% (w/v) SDS, 0.01% (w/v) bromphenol
blue), boiled for 4 min at 100 °C, and separated by electropho-
resis on 7.5% (w/v) SDS-PAGE gel running continuously at 90 V
(29). Wet slab-gels were scanned for fluorescence using a
Typhoon Variable Mode Imager (Amersham Biosciences)
using EX 488 nm and EM 520 nm (band pass filter 40 nm) for
green fluorescent ABPs 1/2. Western blotting for C-terminally,
myc-tagged recombinant proteins was accomplished by run-
ning identically treated samples of 100 g of total protein and
transfer of the samples onto a nitrocellulose membrane for 1 h
at 12 V followed by blocking the membrane with 2% (w/v) BSA
in TBST buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.1%
(v/v) Tween 20). Next, the blots were incubated overnight with
1:2,000 diluted primary mouse -myc mAb (Cell Signaling,
b118, 2% (w/v) BSA in TBST) at 4 °C, washing with TBST for 20
min (repeated 6 times), subsequently incubated with 1:10,000
diluted secondary rabbit -mouse IRD680 (Cell Signaling, 2%
(w/v) BSA in TBST) at room temperature, washed with TBST
for 20 min (repeated 6 times), and finally, read-out occurred on
an Odyssey Infrared Scanner (Li-Cor).
Sodium Azide-mediated Rescue of Enzymatic Activity—Sam-
ples were incubated with ABP (with 10 g of total protein) or
artificial substrate (with 100 g of total protein) in the presence
of 0 –5 M sodium azide (solubilized in 10 mM Tris-HCl, adjusted
to the optimal pH for each enzyme). As elegantly described
earlier (see Ref 33), the presence of (sodium) azide can rescue
the enzymatic activity in the absence of the nucleophile or that
of the acid/base residue. After substrate reactions, tubes were
centrifuged (3000 rpm for 3 min at room temperature) after
which the supernatant was collected and vigorously mixed, and
liberated chromogenic/fluorogenic product was measured.
After ABP labeling reactions, proteins were precipitated with
10% (w/v) trichloroacetic acid for 10 min on ice and centrifuged
at 10,000 rpm for 10 min at 4 °C, and the resulting pellet was
washed 3 times with cold 50% (v/v) acetone in nanopure water
before further use for His-tag pulldown or directly solubilized
in 1 Laemmli buffer and applied to SDS-PAGE. Rescue of
ABP labeling by the addition of acetic acid (10 M) or formic acid
(15 M) followed exactly the same procedure.
RESULTS
Elucidation of the Acid/Base and Nucleophile in GBA—The
nucleophile (Glu-340) and acid/base (Glu-235) of GBA have
been identified unequivocally (Fig. 2a) (29, 39), and we there-
fore used this enzyme to validate our envisioned method where
nucleophile-modifying cyclophellitol ABPs can distinguish the
location of the acid/base and nucleophile in retaining -gluco-
sidases. Accordingly, GBA isoforms with substituted nucleo-
phile and/or acid/base residues were generated. COS-7 cells
TABLE 1
Primers employed for the site-directed mutagenesis of GBA, GBA2, GBA3, and LPH
Coding sequence Substitution Direction Primer sequence (53 3)
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were transfected with constructs expressing C-terminally
myc/His-tagged human GBA or variants with E235G, E235Q,
E340G, E340Q, or E235G/E340G substitutions. All mutagenized
GBA proteins were deficient in enzymatic activity toward the arti-
ficial substrates 4MU-, 4NP-, and 2,4DNP--D-Glc (Fig. 2b).
Next, we attempted to rescue the enzymatic activity of the
aforementioned GBA mutants by co-incubating a fixed con-
centration of artificial substrate together with a range of
sodium azide concentrations. In this context, azide acts as
exogenous anion and is at certain concentrations able to sub-
stitute the absent acid/base or nucleophilic residue (Fig. 1, f and
g) (31, 33, 42). The use of sodium azide has become an impor-
tant staple in the laboratory toolkit available for catalytic resi-
due discovery and has been thoroughly reviewed by Ly and
Withers (32), and its use is elegantly described in manuscripts
such as Bravman et al. (33).
Titration of the various GBA mutants with sodium azide did
not result in an enhanced hydrolysis rate (i.e. rescue) of the
acid/base and nucleophile mutants in combination with fluo-
rogenic 4MU--D-Glc (Fig. 2c). Partial, although significant
rescue was observed with 4NP--D-Glc except for the double
E235G/E340G GBA mutant, which lacks both the acid/base
and nucleophile (Fig. 2b). The most pronounced rescue was
achieved with 2,4DNP--D-Glc (Fig. 2e). This can readily be
explained by considering that 4-methylumbelliferone (4MU)
and 4-nitrophenol (4NP) are inferior leaving groups to 2,4-di-
nitrophenol (2,4DNP), and all require activation by protonation
by the acid/base in the glucosylation step (31–33). At high con-
centrations, sodium azide severely impaired activity of GBA
toward all artificial substrates tested (Fig. 2, d–f).
A final step the classic approach to determine the definite loca-
tion of the acid/base and nucleophile is determination of the ste-
reochemistry of the reaction products, formed during the pres-
ence of sodium azide in combination with the various mutants
(31–33, 42). This methodology hinges on the feasibility of isola-
tion/purification of, first, the mutagenized glycosidase and, sec-
ond, of the various azido products. We propose the use of specific,
fluorescent cyclophellitol-type ABPs. The ABPs described are
highly specific, only bind to the nucleophilic residue, and enable
the sensitive detection of attomoles of ABP-labeled retaining
-glucosidases on slab gels (29, 30). In addition, mutagenized pro-
teins can be labeled directly within complex lysates and living cells
(29, 30) and can be, when required, purified before gel electropho-
resis. To illustrate this ABP application, complete lysates of COS-7
cells expressing recombinant wild-type or mutant GBA were incu-
bated with -epoxide 1 or -aziridine 2 and thereafter purified via
their His tag with TALON beads. Thereafter, the labeled GBA was
visualized by SDS-PAGE and subsequent fluorescence scanning
(Fig. 3a).
The use of 10 g of total protein as the source for ABP label-
ing and subsequent purification step enabled evident detection
of 12 ng (i.e. 200 fmol) of recombinant and ABP-labeled GBA
molecules on gel by using a Typhoon Variable Mode Imager
(Amersham Biosciences) with medium sensitivity settings. In
contrast, the limit of detection of the GBA loading control via
Western blotting for the myc epitope required at least 100 g of
total protein to be loaded on the gel (Fig. 3a).
-Epoxide 1 requires a priori a protonated acid/base and
thus did not label E235G and E235Q GBA. Sodium azide com-
pletely restored the ability of E235G and E235Q GBA variants
FIGURE 2. Proof-of-principle; rescue of substrate hydrolysis. a, schematic depicting GBA with active-site pocket presenting acid/base Glu-235 (left, gray) and
nucleophile Glu-340 (right, black). b, structure formulas of 4MU-, 4NP-, and 4MU--D-Glc. c, catalytic activity of GBA variants toward 4MU-, 4NP-, and 2,4DNP-
-D-Glc relative to mock (black, hatched, white columns, respectively). Shown is sodium azide-mediated rescue of hydrolysis of 4MU (d)-, 4NP (e)-, and 2,4DNP-
-D-Glc (f) by mock (empty plasmid, open circles), wild-type GBA (filled circles), E235G (gray triangles), E235Q (gray circles), E340G (gray squares), E340Q (gray
diamonds), and E235G/E340G (black squares). Data are the average of triplicates  S.D. with one-way analysis of variance significance; *, p  0.05; ***, p  0.001.
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to label with ABP 1 by acting as an external acid/base in the
form of hydrazoic acid (HN3; Fig. 3b). Labeling of acid/base
mutants E235G and E235Q with ABP 1 reached its maximal
intensity when using sodium azide (Fig. 3b) at concentrations
where no rescue in catalytic activity could be identified when
using 2,4DNP--D-Glc (Fig. 2, d–f). The combination of sodium
azide with latter substrate did not reach wild-type activity levels,
even at optimal conditions. Complete restoration of ABP 1 label-
ing was also obtained when acetic acid (HAc) or formic acid (HFo)
were added instead of sodium azide (Fig. 3c).
-Aziridine 2 reacts with the nucleophile Glu-340 regardless
of the acid/base status in GBA molecules and independently of
the presence of sodium azide (Fig. 3, a and b) (30). Substitutions
of nucleophile Glu-340 in GBA to Glu-340 or Gln-340 inher-
ently prevented labeling by both ABP classes (Fig. 3b). Having
established that ABPs 1 and 2 indeed can be employed to sen-
sitively differentiate the acid/base from nucleophilic residue as
compared with the classic sodium azide rescue approach, we
next applied the developed method to the other known human
retaining -glucosidases.
Elucidation of the Acid/Base and Nucleophile in GBA3 from
CaZY Family GH1—We next analyzed the applicability of the
ABP-labeling approach for the cytosolic retaining -glucosi-
dase GBA3, which is categorized in CAZy family GH1 and
which is non-homologous to GBA (GH30, see also Fig. 1a).
Crystallography studies of GBA3 strongly indicate that residues
Glu-165 and Glu-373 function as its acid/base and nucleophile,
respectively (Fig. 4a) (40). Mutated GBA3 containing E165G
and/or E373G displayed no activity toward 4MU-, 4NP-, and
2,4DNP--D-Glc (Fig. 4b). Titration with sodium azide resulted
in a minor but significant activity rescue for E165G, whereas the
E373G mutant did not hydrolyze 4NP--D-Glc, indicating their
involvement in substrate catalysis (Fig. 4c). A more evident res-
cue of activity was observed by using 2,4DNP--D-Glc as sub-
strate (Fig. 4d).
Substitution of Glu-373 prevented GBA3 labeling by both
ABP 1 and 2, whereas substitution of Glu-165 allowed labeling
by -aziridine ABP 2 but not by -epoxide 1, indicating Glu-
165 functions as acid/base. This role was further confirmed by
rescue of -epoxide 1 labeling with sodium azide (Fig. 4e). Our
results confirm the prior indications that indeed Glu-373 is the
nucleophile and Glu-165 the acid/base residue in GBA3. More
importantly, the results illustrate the developed method can be
applied to retaining -glucosidases non-homologous to GBA
(GH30), categorized in other CaZY families such as GH1.
Elucidation of the Acid/Base and Nucleophile in LPH,
Another Member of GH1—Lactase/phlorizin hydrolase con-
tains four domains with high homology with GBA3 and other
GH1 family members (16-18). Two LPH domains, coded III and
IV, have functional catalytic pockets with acid/bases Glu-1065
and Glu-1538 and nucleophiles Glu-1273 and Glu-1749,
respectively (Fig. 5a) (16-18, 41). Pocket III possesses predom-
inantly -glucosidase activity, whereas pocket IV catalyzes the
hydrolysis of -galactosides including lactose. We noted earlier
that LPH can be labeled by both -epoxide 1 and -aziridine 2,
but the site of modification was not established (29, 30).
FIGURE 3. Proof-of-principle; ABP labeling of GBA. a, overexpressed myc/His-tagged GBA variants in total COS-7 cells with excess ABP 1 or ABP 2 and
subsequently purified via His-tag pulldown. Labeling with ABP 1 in the absence/presence of sodium azide (first, second gel), idem with ABP 2 (third and fourth
gel), and GBA detected with -myc (fifth gel). b, -epoxide 1 and -aziridine 2 labeling at different sodium azide concentrations. c, rescue of labeling with small
acids. Labeling of wild-type GBA and acid/base mutants E235G and E235Q at pH 5.2 with -epoxide 1 in the absence or presence of 1 M sodium azide (forms
hydrazoic acid (HN3)), 10 M acetic acid (HAc), or 15 M formic acid (HFo), and subsequently purification via His-tag pulldown is shown. Inter-gel comparisons
facilitated by excess imiglucerase labeled with 50 fm ABP 1 (asterisk) as positive control.
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FIGURE 4. Cytosolic -glucosidase GBA3. a, schematic depicting GBA3 with predicted acid/base (left, gray) and nucleophile (right, black). b, catalytic activity
of GBA3 variants toward 4MU-, 4NP-, and 2,4DNP--D-Glc relative to mock (black, hatched, white columns, respectively). Sodium azide-mediated rescue of 4NP
(c)- and 2,4DNP--D-Glc (d) hydrolysis by mock (empty plasmid, open circles), wild-type GBA3 (filled circles), E165G (gray triangles), E373Q (gray circles), and
E165G/E373G (black squares). e, overexpressed myc/His-tagged GBA3 variants in total COS-7 cells with excess ABP 1 or ABP 2 and subsequently purified via
His-tag pulldown. Labeling with ABP 1 in the absence/presence of sodium azide (first and second gels), idem with ABP 2 (third and fourth gel), and GBA3 detected
with -myc (fifth gel). Data are the average of triplicates  S.D., with one-way analysis of variance significance; ***, p  0.001.
FIGURE 5. Lactase/phlorizin hydrolase LPH. a, schematic depicting LPH with predicted acid/base (Glu-1065, Glu-1538) and nucleophile (Glu-1273, Glu-1749)
for both pockets III and IV. b, catalytic activity of LPH variants toward 4MU-, 4NP-, and 2,4DNP--D-Glc relative to mock (black, hatched, white columns,
respectively). c, sodium azide-mediated rescue of 2,4DNP--D-Glc hydrolysis by mock (empty plasmid, open circles), wild-type LPH (closed circles), E1065G (gray
triangles), E1273G (gray circles), E1538G (gray squares), E1749G (gray diamonds), and E1273G/E1749G (black squares). d, glucose liberation from lactose by LPH
variants, relative to mock. e, overexpressed myc/His-tagged LPH variants in total COS-7 cells with excess ABP 1 or ABP 2 and subsequently purified via His-tag
pulldown. Labeling with ABP 1 in the absence/presence of sodium azide (first and second gel), idem with ABP 2 (third and fourth gel), and LPH detected with
-myc (fifth gel). Data are the average of triplicates  S.D., with one-way analysis of variance significance; *, p  0.05; ***, p  0.001.
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Substitution of the acid/base Glu-1065 or nucleophile Glu-
1273, both residing in pocket III, to a glycine residue decreased
the hydrolysis rate of 4MU-, 4NP-, and 2,4DNP--D-Glc sub-
strates by 89 –93% (Fig. 5b). The addition of sodium azide
restored activity of Glu-1065- and Glu-1273-substituted LPH
toward 2,4DNP--D-Glc (Fig. 5c) and to a lesser extent to 4NP-
-D-Glc. Release of glucose from lactose is 92–96% decreased
by the E1538G and E1749G substitutions in pocket IV (Fig. 5d).
Substitution of catalytic residues in pocket III, E1065G and
E1273G, also affect the hydrolysis of lactose in pocket IV
(reduction by 63– 67%), similar to previous published data (Fig.
5d) (41). In contrast, LPH molecules with substitutions in
pocket IV (E1538G and E1749G) show normal hydrolysis of
2,4DNP--D-Glc in pocket III (Fig. 5, b and c). Similarly, LPH
molecules with substitutions in both pockets III and IV are
completely restored by sodium azide to wild-type -glucosi-
dase activity (Fig. 5c).
Labeling of G1065 LPH with -epoxide 1 only occurred in
the presence of sodium azide, whereas labeling of this mutant
with -aziridine 2 was independent of the presence of sodium
azide, confirming Glu-1065 acts as an acid/base residue (Fig.
5e). The Gly-1273 LPH variant did not bind ABP 1 or ABP 2 in
the absence or presence of sodium azide (Fig. 5e), whereas its
enzymatic activity was rescued (2,4DNP--D-Glc; Fig. 5c), indi-
cating that Glu-1273 is indeed the nucleophile of pocket III.
Pocket IV of LPH appears not targeted by ABPs 1 or 2 as
mutagenesis of its nucleophile and acid/base residue (Glu-1538
and Glu-1749, respectively) did not influence ABP labeling (Fig.
5e) nor did it result in a significantly reduced -glucosidase
activity (Fig. 5b). It seems, therefore, that substitutions in
pocket IV have little impact on pocket III but, intriguingly, not
vice versa. Wild-type LPH is irreversibly inhibited by ABPs 1 and
2 in its hydrolysis of 2,4DNP--D-Glc, and relatively low IC50 val-
ues were observed (1.3–1.4 and 0.19–0.21 M for ABP 1 and 2,
respectively). In contrast, ABP 1 and ABP 2 are not potent irre-
versible inhibitors of lactose hydrolysis mediated by -galactosid-
ase pocket IV, again indicating that the activity-based probes bind
exclusively to the -glucosidase pocket III of LPH.
Klotho, Klotho, and KLPH—Sequence analysis indicates that
KLPH possesses one pocket, and klotho and klotho have two
pockets. Moreover, each is predicted to lack either an acid/base or
nucleophile residue (Fig. 6a). The absence of -glucosidase activity
toward 4MU-, 4NP-, and 2,4DNP--D-Glc was confirmed by no
demonstrable ABP labeling (Fig. 6b). Consistently, even after incu-
bations of 18 h with an excess of either ABP (1 mM) and the pres-
ence of sodium azide, no labeling was observed.
Elucidation of the Acid/Base and Nucleophile in GBA2, a
Member of GH116 —The non-lysosomal -glucosidase GBA2
has recently received considerable attention, but its catalytic
residues currently remain elusive (7–12). Recently, Cobucci-
FIGURE 6. Klotho, klotho, and KLPH. a, schematic depicting klotho, klotho and KLPH with putative acid/bases (gray) and nucleophiles (black) in predicted
pockets. b, overexpressed myc/His-tagged klotho, klotho, KLPH, GBA wild-type, and acid/base-lacking E235G GBA in total COS-7 cells with excess ABP 1 or
ABP 2 and purified via His-tag pulldown. Labeling with ABP 1 in the absence/presence of sodium azide (first and second gel), idem with ABP 2 (third and fourth
gel), and myc-tagged proteins detected with -myc (fifth gel).
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Ponzano et al. (42) identified the acid/base and nucleophile of
the GBA2 homologue SSO1353 (GH116) from S. solfataricus
via sodium azide rescue of mutagenized SSO1353 proteins and
labeling with 2-deoxy-2-fluoroglucoside. Albeit SSO1353
shares low homology with human GBA2, its nucleophile (Glu-
335) and acid/base (Asp-462) appear conserved between spe-
cies, and the authors, therefore, suggest these catalytic residues
are located at Glu-527 and Asp-677 in human GBA2 (42).
Amino acid alignments of GBA2 homologues expressed by
various species revealed, besides Glu-335 and Asp-462, addi-
tional conserved aspartate and glutamate residues that may
have a role in the catalytic mechanism (Fig. 7, a and b). We,
therefore, substituted the conserved aspartate and glutamate
residues individually for glycine (E527G, D659G, D663G,
E667G, D673G, and D677G; see Fig. 7a). Cells were then trans-
fected with C-terminally myc/His-tagged human wild-type
GBA2 or the aforementioned isoforms. Each isoform exhibited
enzymatic activity toward 4MU-, 4NP-, and 2,4DNP--D-Glc
substrates, except Glu-527- and Asp-677-substituted GBA2
(Fig. 8a). Titration with sodium azide subsequently revealed
activity-rescue toward 2,4DNP--D-Glc only in the case of Gly-
527 and Gly-677 GBA2, consistent with a catalytic role (Fig. 8b).
Use of 4NP--D-Glc gave similar results.
Finally, the acid/base and nucleophile were thereafter iden-
tified by labeling total cell lysates containing Gly-527 and Gly-
677 GBA2 with -epoxide 1 or -aziridine 2 and subsequent
fluorescence scanning of SDS-PAGE slab-gels (Fig. 8c). -Ep-
oxide 1 did not bind covalently to GBA2 as previously reported
(29, 30). -Aziridine 2 labeled all GBA2 isoforms, except GBA2,
carrying the E527G substitution, indicating Glu-527 is the
putative nucleophile of GBA2. Labeling of G677 GBA2 by
-aziridine ABP 2 together with its susceptibility for activity-
rescue by sodium azide in combination with 4NP- and 2,4DNP-
-D-Glc substrate indicates that Asp-677 is the acid/base in
GBA2.
The designation of Glu-527 as the nucleophile and Asp-677
as the acid/base in human GBA2 overlaps with the location of
these residues identified in SSO1353 of S. solfataricus (see Fig.
8a) and at their suggested locations in human GBA2 as extra-
polated from the data from S. solfataricus (42).
DISCUSSION
Retaining -glucosidases fulfill important functions in the
human body as is perhaps illustrated best by the deleterious
consequences of GBA deficiency causing Gaucher disease and
the emerging implication of GBA2 in cancer and neuronal
pathologies. Better understanding of human -glucosidases
requires identification of their crucial catalytic amino acids for
catalysis, the nucleophile, and acid/base residues.
Elegant methodologies have been developed in the past to
identify these key residues, such as the use of sodium azide as an
external acid/base and/or nucleophile, allowing catalytic activ-
ity rescue of enzyme molecules with a mutant catalytic residue
and NMR analysis of the resultant product (31–33), or trapping
the nucleophile with a 2-deoxy-2-fluoroglycoside and identifi-
cation via mass-spectrometric detection. These methodologies
hinge on the ability to isolate the wild-type or mutagenized
enzyme before analysis, a feat usually reserved for at least partly
soluble enzymes, and the feasibility to purify sufficient 2-deoxy-
2-fluoroglycoside-labeled peptide or azido-glycoside from the
treated samples.
We have described here a complementary method that com-
bines the previously reported sodium azide-mediated rescue of
enzyme activity to identify the catalytic residues with ABP-la-
beling in complex lysates to directly discriminate between the
acid/base and the nucleophile. ABP labeling can occur directly
with high specificity within living cells (data not shown) or in
total lysate (29, 30), after which, if required, the recombinant
retaining -glucosidases can be purified via for instance an
implemented His tag.
We capitalize on the unique features of epoxide-containing
ABP 1 and aziridine-containing ABP 2, which fundamentally
differ in their ability to label retaining -glucosidases. Both
ABPs bind covalently to the nucleophile, but -epoxide 1
FIGURE 7. Mapping of catalytic residues in GBA2. a, schematic depicting GBA2 putative catalytic residues (shades of gray), with possible acid/base D667 (left,
gray) and nucleophile Glu-527 (black). b, sequence alignment of GBA2 homologues of various species, with highly conserved aspartic (D) and glutamic acids (E).
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requires a functional acid/base, whereas -aziridine 2 does not.
Upon labeling of the nucleophile with the fluorescent ABP, the
protein can be detected by highly sensitive fluorescence scan-
ning of SDS-PAGE slab-gels.
The high sensitivity of the presented method warrants dis-
cussion. Emitted fluorescence from ABP-labeled proteins on
slab-gels can be detected in the attomole range (29), and here 50
femtomoles (i.e. 3 ng) of recombinant GBA, labeled with either
ABPs, were clearly visualized. This is in sharp contrast to the at
least 10-fold higher protein input minimally required for detec-
tion by Western blot and in the enzymatic assays. Therefore,
relatively small amounts of recombinant enzymes expressed by
mammalian cells after transfection are sufficient for accurate
detection with fluorescent ABPs (29, 30).
As we demonstrated, -aziridine 2 reacts with the nucleo-
phile of GBA, GBA2, GBA3, and the -glucosidase pocket III of
LPH to form a stable covalent adduct through a mechanism
independent of the presence of a functional acid/base residue.
In contrast, labeling by -epoxide 1 of GBA, GBA3, and the
-glucosidase pocket III of LPH is prohibited by mutation of
the acid/base, coinciding with loss of enzymatic activity that is
the result of such mutations. Both enzyme activity and -epox-
ide 1 labeling in these mutants can be restored by the addition
of sodium azide as external acid/base. Binding of ABP 1 to the
nucleophile in absence of the acid/base is completely rescued
by employing several orders of magnitude less azide than
required for substrate hydrolysis rescue.
Combining the outcome of fluorescent labeling with ABP 1
and 2 of wild-type and site-directed mutagenized -glucosi-
dases with the sodium azide-mediated rescue of their enzy-
matic activity and labeling allowed us to identify the acid/base
and nucleophile in all human -glucosidases studied: GBA
(Glu-235/Glu-340), GBA3 (Glu-165/Glu-373), LPH (pocket III:
Glu-1065/Glu-1273), and GBA2 (Asp-677/Glu-527). The cata-
lytic residues designated in human GBA2 overlap with the
recently identified acid/base and nucleophile in the GBA2-ho-
mologue SSO1353 from S. solfataricus (42) and their suggested
locations in human GBA2. We noted that the proteins klotho,
klotho, and KLPH, although evolved from -glucosidases
given the close homology to members of GH1, are not labeled
by either ABP, consistent with their lack of -glucosidase activ-
ity, due to the absence of either a nucleophile or acid/base res-
idue in their proposed structure.
In conclusion, our study demonstrates the versatility of com-
bined use of cyclophellitol-based ABPs 1 and 2 in the highly
sensitive identification of the acid/base and nucleophile resi-
dues via direct visualization on slab-gels. Rescue of enzyme
activity with sodium azide in combination with selective ABP
labeling of the nucleophile with -aziridine 2 in the absence of
the acid/base residue may serve as a general approach to dis-
criminate between the catalytic residues of retaining -gluco-
sidases using fluorescence scanning of gels as a read-out. -Ep-
oxide 1 labeling in the presence or absence of sodium azide may
be used to validate the results obtained with -aziridine 2 in
enzymes that tolerate labeling by this ABP. Broadening of this
approach beyond -glucosidases to other classes of retaining
glycosidases should be feasible through variation of the
cyclophellitol core structure (30).
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